Previous 10 | Next 10 |
CAMBRIDGE, Mass., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that on February 23, 2023, the U.S. Food and Drug Admi...
Summary Facioscapulohumeral muscular dystrophy (FSHD) is a rare genetic disorder that affects the muscles of the face, shoulder blades, and upper arms, with a significant impact on the lives of those afflicted. Currently, there is no cure for FSHD, and available treatments only focus on...
CAMBRIDGE, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in a virtual presenta...
Fulcrum Therapeutics ( NASDAQ: FULC ) is down 6.0% after-hours after the firm has priced an underwritten public offering of 9,615,384 shares of its common stock at a public offering price of $13.00/share for expected gross proceeds to be $125M. All shares in the offering are t...
CAMBRIDGE, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the pricing of an underwritten public off...
Clinical-stage biopharmaceutical company Fulcrum Therapeutics ( NASDAQ: FULC ) has commenced a $100M underwritten public offering of shares. The company, selling all the shares in the offering, also intends to grant the underwriters a 30-day option to purchase up to an additional $15M...
Clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, Fulcrum Therapeutics ( NASDAQ: FULC ) announced CEO Robert J. Gould, Ph.D., former president and founding CEO has been appointed as interim CEO as Brya...
― FTX-6058 granted Fast Track Designation for sickle cell disease (SCD) from FDA in December 2022 ― ― Completed enrollment in 6 mg and 2 mg dose cohorts of the Phase 1b trial of FTX-6058 in SCD; enrollment ongoing in 12 mg dose cohort ― ― Additional ...
Summary Shares have lost 20% in the past year. Avidity seeks to tackle a fundamental challenge in the RNA space, namely delivery outside the liver via AOC platform technology. AOC 1001 in DM1 achieved proof of concept as reflected in promising DMPK knockdown, splicing changes, and i...
CAMBRIDGE, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that the Company granted non-statutory stock opti...
News, Short Squeeze, Breakout and More Instantly...
Fulcrum Therapeutics Inc. Company Name:
FULC Stock Symbol:
NYSE Market:
Fulcrum Therapeutics Inc. Website:
CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today a...
CAMBRIDGE, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today a...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...